Drug Profile
Research programme: cancer therapeutics - Domain Therapeutics/ The Candiolo Cancer Institute
Alternative Names: SEMA-3A - Domain Therapeutics/ The Candiolo Cancer InstituteLatest Information Update: 28 Oct 2020
Price :
$50
*
At a glance
- Originator Domain Therapeutics; Instituto di Candiolo
- Developer Domain Therapeutics
- Class Antineoplastics; Membrane proteins
- Mechanism of Action Angiogenesis inhibitors; Neoplasm protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for research development in Cancer in Canada (Parenteral)
- 28 Oct 2020 No recent reports of development identified for research development in Cancer in Italy (Parenteral)
- 19 Sep 2016 Early research in Cancer in Canada (Parenteral) before September 2016